FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211619114> ?p ?o ?g. }

• W3211619114 endingPage "S3" @default.
• W3211619114 startingPage "S2" @default.
• W3211619114 abstract "Background The role of upfront ASCT for NDTE MM remains under evaluation with high MRD rates following novel induction and consolidation (cons) strategies. K maintenance represents an alternative strategy to lenalidomide maintenance. The CARDAMON trial investigated K maintenance following KCd induction plus either ASCT or KCd cons. Methods NDTE pts received 4 x KCd induction (K 20/56 mg/m2 biweekly, C 500 mg D 1,8,15, d 40mg weekly) before 1:1 randomisation to ASCT or 4 x KCd cons followed by 18 cycles K maintenance (56mg/m2 D1,8,15). Flow cytometric MRD (10-5) was assessed post induction, pre-maintenance and at 6 months maintenance. Primary endpoints were ≥VGPR post induction and 2-year PFS from randomisation. Secondary endpoints included improvements in disease response and MRD conversion following ASCT/ cons and maintenance. Results 281 patients were registered, with 218 randomised to either ASCT or cons. The median PFS for ASCT was not yet reached vs 3.4 years for cons, with cons failing to show non-inferiority (difference in 2-year PFS 6.5%, 70% CI 1.0% to 11.1%). 196 patients received K maintenance (99 ASCT, 97 cons), 17 remain on treatment. A median of 16 cycles (1-18) were given over a median of 15.9 months (0-21.5). COVID-19 led to maintenance treatment interruptions in 41 (8 ASCT, 6 Cons) and treatment discontinuation in 15 (9 ASCT, 6 Cons). The median K dose given was 50.6mg/m2 and was similar across both arms (51.2 vs 49.4mg/m2, p=0.03). K maintenance was discontinued for PD in 14.1% (ASCT) vs 22.7% (cons), and for adverse events (AEs) in 7.1% (ASCT) vs 4.1% (cons). Most common AEs were hypertension and infections and more ≥G3 AEs were noted in ASCT vs cons (p=0.01). Patient/ clinician withdrawals from maintenance were low but occurred more in the ASCT arm (9.1% vs 1%). MRD neg patients post ASCT/ Cons had a longer PFS than MRD pos (p=0.002); with a higher MRD neg rate in the ASCT arm (53.6% vs 35.1% in Cons, p=0.01). MRD neg patients at 6 months post maintenance also had longer PFS (p=0.004 cf MRD pos patients); again with higher MRD neg rates in the ASCT arm (58.1% ASCT vs 40.5% Cons, p=0.02). There was no difference in PFS for MRD neg patients according to treatment arm from PBSCH, post-ASCT/ Cons or 6 months maintenance timepoints. Overall, 27.8% of MRD pos patients converted to MRD neg post ASCT/ Cons with more converting with ASCT (39.1% ASCT vs 16.1%, p=0.004). 23.5% of MRD pos patients converted to neg during maintenance (30.6% ASCT, 17.8%: p=0.2). Maintenance of MRD negativity over the first 6 months was similar between ASCT and Cons arms (p=0.3). There was no evidence that the timing of achievement of MRD negativity impacted PFS. Conclusions K maintenance at 56mg/m2 weekly was deliverable and tolerable, with continued higher MRD neg rates at 6 months post-ASCT compared to post-Cons. However more ≥G3 AEs and discontinuations for AEs/ patient choice were noted for K maintenance after ASCT. The role of upfront ASCT for NDTE MM remains under evaluation with high MRD rates following novel induction and consolidation (cons) strategies. K maintenance represents an alternative strategy to lenalidomide maintenance. The CARDAMON trial investigated K maintenance following KCd induction plus either ASCT or KCd cons. NDTE pts received 4 x KCd induction (K 20/56 mg/m2 biweekly, C 500 mg D 1,8,15, d 40mg weekly) before 1:1 randomisation to ASCT or 4 x KCd cons followed by 18 cycles K maintenance (56mg/m2 D1,8,15). Flow cytometric MRD (10-5) was assessed post induction, pre-maintenance and at 6 months maintenance. Primary endpoints were ≥VGPR post induction and 2-year PFS from randomisation. Secondary endpoints included improvements in disease response and MRD conversion following ASCT/ cons and maintenance. 281 patients were registered, with 218 randomised to either ASCT or cons. The median PFS for ASCT was not yet reached vs 3.4 years for cons, with cons failing to show non-inferiority (difference in 2-year PFS 6.5%, 70% CI 1.0% to 11.1%). 196 patients received K maintenance (99 ASCT, 97 cons), 17 remain on treatment. A median of 16 cycles (1-18) were given over a median of 15.9 months (0-21.5). COVID-19 led to maintenance treatment interruptions in 41 (8 ASCT, 6 Cons) and treatment discontinuation in 15 (9 ASCT, 6 Cons). The median K dose given was 50.6mg/m2 and was similar across both arms (51.2 vs 49.4mg/m2, p=0.03). K maintenance was discontinued for PD in 14.1% (ASCT) vs 22.7% (cons), and for adverse events (AEs) in 7.1% (ASCT) vs 4.1% (cons). Most common AEs were hypertension and infections and more ≥G3 AEs were noted in ASCT vs cons (p=0.01). Patient/ clinician withdrawals from maintenance were low but occurred more in the ASCT arm (9.1% vs 1%). MRD neg patients post ASCT/ Cons had a longer PFS than MRD pos (p=0.002); with a higher MRD neg rate in the ASCT arm (53.6% vs 35.1% in Cons, p=0.01). MRD neg patients at 6 months post maintenance also had longer PFS (p=0.004 cf MRD pos patients); again with higher MRD neg rates in the ASCT arm (58.1% ASCT vs 40.5% Cons, p=0.02). There was no difference in PFS for MRD neg patients according to treatment arm from PBSCH, post-ASCT/ Cons or 6 months maintenance timepoints. Overall, 27.8% of MRD pos patients converted to MRD neg post ASCT/ Cons with more converting with ASCT (39.1% ASCT vs 16.1%, p=0.004). 23.5% of MRD pos patients converted to neg during maintenance (30.6% ASCT, 17.8%: p=0.2). Maintenance of MRD negativity over the first 6 months was similar between ASCT and Cons arms (p=0.3). There was no evidence that the timing of achievement of MRD negativity impacted PFS. K maintenance at 56mg/m2 weekly was deliverable and tolerable, with continued higher MRD neg rates at 6 months post-ASCT compared to post-Cons. However more ≥G3 AEs and discontinuations for AEs/ patient choice were noted for K maintenance after ASCT." @default.
• W3211619114 created "2021-11-22" @default.
• W3211619114 creator A5007401286 @default.
• W3211619114 creator A5025879031 @default.
• W3211619114 creator A5026876598 @default.
• W3211619114 creator A5028381731 @default.
• W3211619114 creator A5038099312 @default.
• W3211619114 creator A5047779823 @default.
• W3211619114 creator A5050819642 @default.
• W3211619114 creator A5059137194 @default.
• W3211619114 creator A5062076815 @default.
• W3211619114 creator A5062329233 @default.
• W3211619114 creator A5062426102 @default.
• W3211619114 creator A5063301766 @default.
• W3211619114 creator A5066026746 @default.
• W3211619114 creator A5068293508 @default.
• W3211619114 creator A5072918409 @default.
• W3211619114 creator A5073537179 @default.
• W3211619114 creator A5075200393 @default.
• W3211619114 creator A5078582113 @default.
• W3211619114 creator A5082564837 @default.
• W3211619114 creator A5083038493 @default.
• W3211619114 creator A5083683919 @default.
• W3211619114 creator A5091082622 @default.
• W3211619114 date "2021-10-01" @default.
• W3211619114 modified "2023-10-16" @default.
• W3211619114 title "OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)" @default.
• W3211619114 doi "https://doi.org/10.1016/s2152-2650(21)02077-2" @default.
• W3211619114 hasPublicationYear "2021" @default.
• W3211619114 type Work @default.
• W3211619114 sameAs 3211619114 @default.
• W3211619114 citedByCount "1" @default.
• W3211619114 countsByYear W32116191142022 @default.
• W3211619114 crossrefType "journal-article" @default.
• W3211619114 hasAuthorship W3211619114A5007401286 @default.
• W3211619114 hasAuthorship W3211619114A5025879031 @default.
• W3211619114 hasAuthorship W3211619114A5026876598 @default.
• W3211619114 hasAuthorship W3211619114A5028381731 @default.
• W3211619114 hasAuthorship W3211619114A5038099312 @default.
• W3211619114 hasAuthorship W3211619114A5047779823 @default.
• W3211619114 hasAuthorship W3211619114A5050819642 @default.
• W3211619114 hasAuthorship W3211619114A5059137194 @default.
• W3211619114 hasAuthorship W3211619114A5062076815 @default.
• W3211619114 hasAuthorship W3211619114A5062329233 @default.
• W3211619114 hasAuthorship W3211619114A5062426102 @default.
• W3211619114 hasAuthorship W3211619114A5063301766 @default.
• W3211619114 hasAuthorship W3211619114A5066026746 @default.
• W3211619114 hasAuthorship W3211619114A5068293508 @default.
• W3211619114 hasAuthorship W3211619114A5072918409 @default.
• W3211619114 hasAuthorship W3211619114A5073537179 @default.
• W3211619114 hasAuthorship W3211619114A5075200393 @default.
• W3211619114 hasAuthorship W3211619114A5078582113 @default.
• W3211619114 hasAuthorship W3211619114A5082564837 @default.
• W3211619114 hasAuthorship W3211619114A5083038493 @default.
• W3211619114 hasAuthorship W3211619114A5083683919 @default.
• W3211619114 hasAuthorship W3211619114A5091082622 @default.
• W3211619114 hasConcept C126322002 @default.
• W3211619114 hasConcept C141071460 @default.
• W3211619114 hasConcept C143998085 @default.
• W3211619114 hasConcept C199360897 @default.
• W3211619114 hasConcept C203092338 @default.
• W3211619114 hasConcept C2776063141 @default.
• W3211619114 hasConcept C2776364478 @default.
• W3211619114 hasConcept C2776694085 @default.
• W3211619114 hasConcept C2778283404 @default.
• W3211619114 hasConcept C2778715236 @default.
• W3211619114 hasConcept C2779050716 @default.
• W3211619114 hasConcept C2780108899 @default.
• W3211619114 hasConcept C2780401358 @default.
• W3211619114 hasConcept C37091826 @default.
• W3211619114 hasConcept C41008148 @default.
• W3211619114 hasConcept C535046627 @default.
• W3211619114 hasConcept C71924100 @default.
• W3211619114 hasConceptScore W3211619114C126322002 @default.
• W3211619114 hasConceptScore W3211619114C141071460 @default.
• W3211619114 hasConceptScore W3211619114C143998085 @default.
• W3211619114 hasConceptScore W3211619114C199360897 @default.
• W3211619114 hasConceptScore W3211619114C203092338 @default.
• W3211619114 hasConceptScore W3211619114C2776063141 @default.
• W3211619114 hasConceptScore W3211619114C2776364478 @default.
• W3211619114 hasConceptScore W3211619114C2776694085 @default.
• W3211619114 hasConceptScore W3211619114C2778283404 @default.
• W3211619114 hasConceptScore W3211619114C2778715236 @default.
• W3211619114 hasConceptScore W3211619114C2779050716 @default.
• W3211619114 hasConceptScore W3211619114C2780108899 @default.
• W3211619114 hasConceptScore W3211619114C2780401358 @default.
• W3211619114 hasConceptScore W3211619114C37091826 @default.
• W3211619114 hasConceptScore W3211619114C41008148 @default.
• W3211619114 hasConceptScore W3211619114C535046627 @default.
• W3211619114 hasConceptScore W3211619114C71924100 @default.
• W3211619114 hasLocation W32116191141 @default.
• W3211619114 hasOpenAccess W3211619114 @default.
• W3211619114 hasPrimaryLocation W32116191141 @default.
• W3211619114 hasRelatedWork W1976201756 @default.
• W3211619114 hasRelatedWork W2340942222 @default.
• W3211619114 hasRelatedWork W2546436011 @default.
• W3211619114 hasRelatedWork W2738602720 @default.
• W3211619114 hasRelatedWork W2904405349 @default.

• next